Filter
797
Text search:
Multidrug
resistant
tuberculosis
Featured
94
189
Language
Document type
498
119
92
30
22
18
7
7
3
1
Countries / Regions
52
37
30
19
19
16
15
12
11
11
11
10
9
9
8
8
8
7
7
7
7
7
6
6
6
6
5
5
5
4
4
4
4
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
218
90
30
20
13
9
6
Toolboxes
411
84
49
19
16
12
12
11
11
9
8
7
7
6
6
6
5
4
4
2
1
Antimicrobial Resistance and Infection Control 2014,3 :31
South Eastern European Journal of Public Health, EEJPH 2016, posted: 11 January 2016. DOI 10.4119/UNIBI/SEEJPH-2016-85
PloS One October 2012 | Volume 7 | Issue 10 | e46943
15. Euro Surveill. 2017;22(47):pii=17-00103
INT J TUBERC LUNG DIS 22(2):197–205 http://dx.doi.org/10.5588/ijtld.17.0245
Emerging Infectious Diseases; Vol. 21, No. 11, November 2015
For full course visit: https://drtbnetwork.org/training-course-MDR-TB
This course has been designed to take three days. It is composed of lectures, in-class readings, exercises, case discussions, and quizzes, which together are intended to provide a diverse and compelling learning experience for pa
...
Following the encouraging initial results of the pilot project, the Ministry of Health is committed to increasing access to MDR-TB diagnosis, treatment and care. An expansion plan for the programmatic management of drug-resistant TB has been develop
...
This report describes the geographical and temporal distribution of multidrug-resistant (MDR) tuberculosis (TB) using molecular typing data repo
...
Rev Panam Salud Publica. 2021;45:e74.
Some characteristics of patients and healthcare providers influence treatment success in MDR-TB cases. Physicians’ and nurses’ knowledge about MDR-TB must be improved, and follow-up of MDR-TB patients who are living with HIV and of those affiliated with the
...
Int. J. Mol. Sci. 2017, 18, 341, 1 - 10
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med
...
Interim policy guidance
Lancet Respir Med 2017; 5: 291–360Vol, 5 April 2017
